Existing biomarkers, such as programmed cell death‐ligand 1 (PD‐L1), mismatch repair (MMR) deficiency, and tumor mutational burden (TMB), were reported to have limited precision to predict clinical outcomes of patients treated with ICIs.4, 5. Here, CD274 is linked to hyperinsulinemic hypoglycemia, familial, 4.